Blood Work Frequency on TRT and Peptide Protocols: What Research Tracks and Why

Most TRT and peptide research protocols follow a similar blood work schedule: **Baseline (before starting)**: full panel including hormones, metabolic markers, lipids, CBC (complete blood count), and liver/kidney function. This establishes your starting point — without it, you cannot tell if a change is due to the protocol or was already present. **6-8 weeks after starting or changing protocol**: reassess the markers most likely to change early — for TRT, testosterone levels, estradiol, hematocrit. For peptides like BPC-157 or TB-500, typically no routine blood work needed but any relevant markers would be assessed here. **3 months in**: full repeat of baseline panel. By 3 months, most protocols have reached steady state, so the 3-month draw represents how the protocol affects you during ongoing use. **6 months**: another full panel to confirm stability and monitor trends. **12 months**: complete panel. If everything is stable and within normal ranges, subsequent testing can typically space to every 6-12 months. **Annual thereafter**: for stable protocols with no changes, annual blood work is generally sufficient — assuming no symptoms, new medications, or protocol changes. **Why this pattern works**: 1. **Capture the transition**: the first 3-6 months is when most changes occur. Frequent testing during this period catches issues early. 2. **Establish stability**: 6-12 months of data confirms the protocol is stable and predictable. 3. **Reduce cost and stress thereafter**: once stable, annual testing balances safety with practicality. More frequent testing doesn't provide meaningful additional information for stable protocols. **Triggers for additional unscheduled blood work**: - New symptoms (fatigue, mood changes, pain, sleep disruption) - Significant dose change (up or down) - Adding new compounds to a stack - Starting or stopping other medications - Signs of polycythemia (hematocrit elevation) — fatigue, headaches, blood pressure rise - Unusual bruising, bleeding, or clotting concerns Log your protocol changes, dosing history, and blood work results in Dosed — the app creates a timeline that correlates your labs with protocol phases, so you can see exactly how each change affected your labs. This content is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any protocol and before interpreting blood work. Individual monitoring needs vary based on your specific protocol, health status, and medical history.

Research on TRT safety has converged on a core panel of markers that should be tracked at each blood draw. Understanding what each measures and why it matters helps you interpret your own results. **Hormone panel**: - **Total testosterone**: measures overall testosterone. Normal range (varies by lab): 300-1,000 ng/dL for men. TRT typically targets the upper half of normal (600-900+). Peak/trough timing matters — different injection schedules produce different peak/trough patterns. - **Free testosterone**: the portion of testosterone not bound to SHBG or albumin. This is the biologically active fraction. Often the more meaningful number than total testosterone. Normal: 50-200 pg/mL. - **Bioavailable testosterone**: total minus tightly bound (SHBG-bound). Another measure of usable testosterone. - **Estradiol (E2)**: testosterone converts to estradiol via aromatase. Monitoring E2 prevents over-suppression (too low = joint pain, libido loss, mood issues) and over-conversion (too high = water retention, emotional volatility, gynecomastia). Target range on TRT: 20-40 pg/mL using the sensitive assay (LC-MS/MS). Older immunoassays have different reference ranges. - **SHBG (sex hormone-binding globulin)**: binds testosterone and estradiol. High SHBG reduces free testosterone availability; low SHBG increases it. Important context for interpreting hormone levels. - **LH and FSH**: typically suppressed on TRT (exogenous testosterone inhibits endogenous production). Measured less frequently after the first 3 months. **Hematologic markers** (blood cell measures — CRITICAL for TRT safety): - **Hemoglobin**: the protein in red blood cells. Normal: 13.5-17.5 g/dL for men. - **Hematocrit**: the percentage of blood volume that is red blood cells. Normal: 41-50% for men. TRT can elevate hematocrit significantly — above 52-54% is generally considered the clinical threshold for intervention (phlebotomy to donate blood, dose reduction, or temporary hold). - **Red blood cell count (RBC)**: similar to hematocrit. Polycythemia (elevated hematocrit) is the most common SAFETY issue with TRT. It increases blood viscosity, which can elevate stroke and cardiovascular risk. Monitoring is non-negotiable. Research studies typically suspend TRT for hematocrit > 54% and require it to return to normal before resuming. **Lipid panel**: - **Total cholesterol, LDL, HDL, triglycerides**: TRT has varied effects on lipids depending on individual and dosing. HDL may decrease modestly. Monitor at baseline and annually thereafter. **Metabolic markers**: - **Glucose, HbA1c**: TRT can improve insulin sensitivity in some individuals with metabolic syndrome. Track at baseline and annually. - **Comprehensive metabolic panel (CMP)**: includes liver enzymes (AST, ALT), kidney function (BUN, creatinine, eGFR), and electrolytes. Generally not affected by TRT but worth monitoring for overall health. **Prostate markers**: - **PSA (prostate-specific antigen)**: concerns about prostate cancer risk with TRT have largely been disproven in research, but PSA monitoring remains standard practice. Check at baseline, 6 months, and annually. Significant rises warrant urology consultation. **Other markers** (case-by-case): - Thyroid panel (TSH, free T4, free T3): if thyroid symptoms are present or at baseline - Vitamin D, B12, iron: general health markers worth monitoring - Inflammation markers (hs-CRP): for cardiovascular risk assessment **Research study protocols** (such as those used by the Testosterone Trials or the TRAVERSE trial) follow similar schedules: baseline, 3 months, 6 months, 12 months, and annually thereafter. This is the research standard for monitoring TRT safety and efficacy. Dosed tracks each of these markers over time and flags trends — not just individual values but the trajectory across multiple draws.

Unlike TRT, many peptides don't require routine blood work monitoring because they don't act through hormone pathways. But some do, and knowing which is which helps you budget testing appropriately. **Peptides that typically don't require routine blood work** (based on research monitoring patterns): - **BPC-157**: used for healing and recovery research. No hormonal impact. Research studies typically monitor by symptoms and specific pathology (e.g., tendon healing imaging, inflammatory markers in some studies). Routine hormone or metabolic testing is not typical. - **TB-500 (Thymosin Beta-4)**: similar profile to BPC-157. Minimal systemic hormonal effect. - **Melanotan II**: affects melanocortin receptors. Research monitoring focuses on skin changes and blood pressure rather than routine blood work. - **GHK-Cu (copper peptides)**: topical or injectable, primarily for skin/hair research. Blood work not typically required. **Peptides that DO require regular blood work**: - **GLP-1 receptor agonists (semaglutide, tirzepatide)**: weight loss and metabolic research. Monitor: fasting glucose, HbA1c (baseline and every 3-6 months), liver enzymes, lipid panel, and thyroid (TSH). Research protocols also monitor for rare but serious side effects (pancreatitis markers, thyroid imaging in some protocols). - **CJC-1295/Ipamorelin (growth hormone secretagogues)**: research on GH stimulation. Monitor: IGF-1 (baseline, 6 weeks, 3 months to confirm GH elevation), glucose (GH can affect insulin sensitivity), and sometimes cortisol (ipamorelin is usually preferred over GHRP-6 or GHRP-2 specifically because it doesn't elevate cortisol). - **Sermorelin**: similar to CJC-1295 research — monitor IGF-1. - **Tesamorelin**: FDA-approved for HIV-associated lipodystrophy. Research monitors IGF-1, glucose, and liver enzymes. - **HGH (human growth hormone)**: not a peptide technically but often grouped. Requires IGF-1 monitoring (target 200-300 ng/mL typically), glucose, thyroid, and sometimes prolactin. HGH elevates glucose and can induce insulin resistance at higher doses. **Combination monitoring for stacks**: If you're running multiple compounds, use the union of their individual monitoring requirements: - TRT + GLP-1: full TRT panel + glucose/HbA1c/lipids more frequently - TRT + CJC-1295/Ipamorelin: full TRT panel + IGF-1 - GLP-1 + BPC-157: GLP-1 metabolic panel (BPC-157 doesn't add much) **Lab timing considerations**: - **Testosterone peak/trough**: timing matters. Same-day testing at the same time relative to your injection gives comparable results over time. A level drawn at trough (day before next injection) vs peak (day after) can differ by 30-50%. - **E2 sensitivity**: request the sensitive LC-MS/MS assay, not the standard immunoassay. Immunoassays can cross-react with other steroids and give inflated readings in men. - **IGF-1**: best drawn in morning, fasting, consistent timing throughout the protocol. - **Glucose/HbA1c**: fasting 10-12 hours before. HbA1c reflects 2-3 months of average glucose, so timing is less critical than for fasting glucose. **Cost considerations**: - **Basic TRT panel quarterly**: $200-$400 through independent lab services (Discounted Labs, Marek Labs, DHA Labs, LabCorp direct services) - **Comprehensive panel with all markers annually**: $400-$800 - **GLP-1 metabolic panel**: $150-$300 - **IGF-1 standalone**: $50-$100 Insurance may cover baseline and annual panels if ordered by a physician for documented medical indications. Research protocols typically run their own bloodwork. Dosed logs which peptides you're running and what markers need to be tracked, generates reminders for blood draws, and correlates your labs with your protocol timeline.

Reading a single lab value is easy. Interpreting a trend over multiple draws — while staying calm about normal fluctuations — is the skill that separates informed research participants from anxious ones. **Principle 1: Single values don't tell the story** A single lab that's slightly out of range doesn't automatically mean something is wrong. Normal lab-to-lab variability is significant. Examples: - **Testosterone**: can vary 100-200 ng/dL day-to-day and even more hour-to-hour based on time of draw, recent meals, sleep, stress - **Hematocrit**: fluctuates with hydration. A dehydrated patient can show 2-4% higher than well-hydrated - **Glucose**: affected by most-recent meal, exercise, stress - **E2**: fluctuates with cortisol rhythms Trust the TREND over multiple draws more than any single value. **Principle 2: Know your target ranges** Each marker has: - **Reference range**: the statistical range for a general population (e.g., testosterone 300-1,000 ng/dL) - **Optimal range**: what research suggests is healthy, which may be narrower than the reference range (e.g., testosterone 600-900) - **Your personal pattern**: what's normal FOR YOU based on baseline and prior draws All three matter. A value in the 'normal' range could still be low for you if your baseline was higher. **Principle 3: When to act on TRT trends** **Testosterone too low (< 500 on TRT)**: - Review dose and injection frequency - Check injection technique (muscle vs subcutaneous, rotation) - Consider increasing frequency (more frequent smaller doses produce more stable levels) - Consult the prescribing physician **Testosterone too high (> 1,200 on TRT)**: - Review dose — likely too high - Consider reducing by 10-20% - Recheck labs after 4-6 weeks - Monitor for side effects (mood, hematocrit, E2) **Estradiol issues**: - Low E2 (< 15): joint pain, libido loss, mood. Consider dose reduction or less aggressive AI use. - High E2 (> 50): water retention, emotional changes, gynecomastia. Sometimes reduced dose or AI adjustment. - Always recheck with sensitive assay before making changes. **Hematocrit rising**: - At 50-52%: monitor closely, increase hydration, consider dose reduction - At 52-54%: consult physician about therapeutic phlebotomy (donating blood) - Above 54%: typically hold TRT until resolved, then resume at lower dose - Rising trend over 3+ draws even if below 54% warrants attention **Lipid changes**: - Modest LDL increase: usually acceptable, monitor annually - Significant HDL decrease: more concerning, may indicate need to adjust protocol - Large trend changes: consult physician, consider lifestyle interventions first **Principle 4: When to act on peptide trends** **GLP-1 + elevated liver enzymes**: - Minor elevation: monitor, usually resolves - Significant elevation (3x upper limit): consult physician, consider hold **IGF-1 on GH secretagogue protocols**: - IGF-1 target typically 200-300 ng/mL for research protocols - Above 350: dose likely too high, increases risk - Below 150: dose may be too low or compound not working as expected **Principle 5: The research monitoring mindset** Research studies monitor blood work to: 1. Confirm safety — no serious adverse trends 2. Confirm efficacy — the protocol is producing intended effects 3. Individualize — adjust doses based on individual response Approach your own labs the same way. Don't chase perfect numbers. Look for: is this safe? Is it working? Does anything need adjustment? **What NOT to do**: - Panic over a single out-of-range value without context - Adjust your own dose based on labs without consulting your prescriber - Test weekly for months trying to find the 'perfect' value - Compare your numbers to someone else's — your baseline and response are unique - Ignore symptoms that contradict 'normal' labs (how you feel matters) - Ignore concerning labs just because you feel fine (some serious issues are silent initially) **What TO do**: - Track labs in a structured format (Dosed or a spreadsheet) - Compare to YOUR baseline, not just reference ranges - Watch for trends across 2-3 draws, not single values - Correlate labs with symptoms and protocol changes - Share labs with your prescribing physician before making changes - Ask questions — healthcare providers can interpret for your specific situation Dosed displays your lab trends over time alongside your protocol timeline, so you can see exactly which changes produced which effects and share comprehensive data with your physician.